CLPT
BEARISH
$9.07
Live
ClearPoint Neuro, Inc. · NASDAQ
Target $25.0
(+175.6%)
$8.6
52W Range
$30.1
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 08, 2026
Market cap
$269.82M
P/E
N/A
ROE
-95.6%
Profit margin
-69.1%
Debt/Equity
2.08
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
65%
CLPT shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Key Strengths
Strong revenue growth of 34.0%
Key Risks
Low profit margin of -69.1%
Weak financial trend (Piotroski F-Score: 1/9)
High debt burden with D/E of 2.08
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
33
Weak
50
65
30
20
0
AI Verdict
CLPT shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 1/9). Concerns include weak profitability or high valuation.
Key drivers: Strong revenue growth of 34.0%, Low profit margin of -69.1%, Weak financial trend (Piotroski F-Score: 1/9)
Confidence
25%
Value
50/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Future
65/100
Rule-based growth outlook.
Positives
- Revenue growth running at 34.0%.
Watchpoints
No urgent risks highlighted.
Past
30/100
Historical performance + price trend: Shares moved -59.8% over 5Y and -17.2% over 1Y.
Positives
- Insufficient data for clear positives.
Watchpoints
- ROE only -95.6%.
- Thin profit margins.
Health
20/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Insufficient data for clear positives.
Watchpoints
- High D/E ratio (2.08).
Dividend
0/100
Dividend policy fallback.
Positives
- Insufficient data for clear positives.
Watchpoints
- No regular dividend payments.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$9.07
Analyst Target
$25.0
Upside/Downside
+175.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for CLPT and closest competitors.
Updated 2026-04-07
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
CLPT
ClearPoint Neuro, Inc.
Primary
|
-59.8% | -1.5% | -17.2% | -65.6% | -21.4% | -0.3% |
|
CARL
Carlsmed, Inc.
Peer
|
-32.8% | -32.8% | -32.8% | -28.3% | -18.4% | +7.6% |
|
CHRS
Coherus Oncology, Inc.
Peer
|
-88.2% | -78.7% | +103.2% | -2.3% | -13.5% | -1.2% |
|
ANL
Adlai Nortye Ltd.
Peer
|
-47.0% | -47.0% | +247.2% | +345.4% | -14.4% | -10.8% |
|
ALEC
Alector, Inc.
Peer
|
-88.2% | -66.9% | +53.9% | -20.0% | +14.6% | +10.0% |
CLP
ClearPoint Neuro, Inc.
Primary
5Y
-59.8%
3Y
-1.5%
1Y
-17.2%
6M
-65.6%
1M
-21.4%
1W
-0.3%
CAR
Carlsmed, Inc.
Peer
5Y
-32.8%
3Y
-32.8%
1Y
-32.8%
6M
-28.3%
1M
-18.4%
1W
+7.6%
CHR
Coherus Oncology, Inc.
Peer
5Y
-88.2%
3Y
-78.7%
1Y
+103.2%
6M
-2.3%
1M
-13.5%
1W
-1.2%
ANL
Adlai Nortye Ltd.
Peer
5Y
-47.0%
3Y
-47.0%
1Y
+247.2%
6M
+345.4%
1M
-14.4%
1W
-10.8%
ALE
Alector, Inc.
Peer
5Y
-88.2%
3Y
-66.9%
1Y
+53.9%
6M
-20.0%
1M
+14.6%
1W
+10.0%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-11.13
PEG Ratio
N/A
P/B Ratio
9.51
P/S Ratio
7.3
EV/Revenue
7.86
EV/EBITDA
-13.53
Market Cap
$269.82M
Profitability
Profit margins and return metrics
Profit Margin
-69.08%
Operating Margin
-50.38%
Gross Margin
61.38%
ROE
-95.64%
ROA
-20.41%
Growth
Revenue and earnings growth rates
Revenue Growth
+34.0%
Earnings Growth
N/A
Q/Q Revenue Growth
+33.96%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
2.08
High debt
Current Ratio
5.91
Strong
Quick Ratio
4.94
Excellent
Cash/Share
$1.55
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Gross Margin
61.5%
Op. Margin
-67.7%
Net Margin
-74.8%
Total Assets
$0.1B
Liabilities
$0.1B
Equity
$0.0B
Debt/Equity
2.49x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-05
$N/A
2026-03-17
$-0.27
-35.0% surprise
2025-11-06
$-0.21
-5.0% surprise
2025-08-12
$-0.21
-5.0% surprise
Healthcare Sector Comparison
Comparing CLPT against 162 companies in the Healthcare sector
(15 bullish, 52 neutral, 95 bearish)
Return on Equity (ROE)
-95.64%
This Stock
vs
-42.35%
Sector Avg
+125.8%
(Excellent)
Profit Margin
-69.08%
This Stock
vs
-18.25%
Sector Avg
+278.6%
(Superior)
Debt to Equity
2.08
This Stock
vs
5.74
Sector Avg
-63.8%
(Less Debt)
Revenue Growth
34.0%
This Stock
vs
114.26%
Sector Avg
-70.2%
(Slower)
Current Ratio
5.91
This Stock
vs
3.36
Sector Avg
+76.0%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
CLPT
ClearPoint Neuro, Inc.
|
BEARISH | $269.82M | - | -95.6% | -69.1% | $9.07 | |
|
CARL
Carlsmed, Inc.
|
NEUTRAL | $260.37M | - | -47.6% | -58.7% | $9.74 | Compare |
|
CHRS
Coherus Oncology, Inc.
|
NEUTRAL | $250.32M | - | -% | 398.4% | $1.67 | Compare |
|
ANL
Adlai Nortye Ltd.
|
BEARISH | $293.36M | - | -139.0% | -% | $7.95 | Compare |
|
ALEC
Alector, Inc.
|
BEARISH | $242.8M | - | -181.6% | -% | $2.2 | Compare |
CLPT
ClearPoint Neuro, Inc.
BEARISH
Mkt Cap
$270M
P/E
-
ROE
-95.6%
Price
$9.07
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | FLETCHER R JOHN | Director | Stock Award | 1,270 | $11,557 |
| 2026-04-01 | GIRIN PASCAL E R | Director | Stock Award | 755 | $6,870 |
| 2026-04-01 | RICHARDS TIMOTHY T | Director | Stock Award | 442 | $4,022 |
| 2026-03-19 | BURNETT JOSEPH MICHAEL | Chief Executive Officer | Option Exercise | 20,942 | $67,852 |
| 2026-03-12 | BURNETT JOSEPH MICHAEL | Chief Executive Officer | Stock Award | 84,829 | - |
| 2026-03-12 | D'ALESSANDRO DANILO | Chief Financial Officer | Stock Award | 32,627 | - |
| 2026-03-12 | STIGALL L JEREMY | Officer | Stock Award | 30,995 | - |
| 2026-03-12 | SABRA MAZIN | Chief Operating Officer | Stock Award | 26,101 | - |
| 2026-03-11 | D'ALESSANDRO DANILO | Chief Financial Officer | Stock Award | 4,145 | - |
| 2026-03-11 | STIGALL L JEREMY | Officer | Stock Award | 8,291 | - |
| 2026-03-06 | BURNETT JOSEPH MICHAEL | Chief Executive Officer | Stock Award | 47,407 | - |
| 2026-03-06 | D'ALESSANDRO DANILO | Chief Financial Officer | Stock Award | 18,765 | - |
| 2026-03-06 | STIGALL L JEREMY | Officer | Stock Award | 17,778 | - |
| 2026-03-06 | SABRA MAZIN | Chief Operating Officer | Stock Award | 13,827 | - |
| 2026-03-03 | BURNETT JOSEPH MICHAEL | Chief Executive Officer | Stock Award | 26,568 | - |
FLETCHER R JOHN
Director
2026-04-01
1,270 shares
·
$11,557
GIRIN PASCAL E R
Director
2026-04-01
755 shares
·
$6,870
RICHARDS TIMOTHY T
Director
2026-04-01
442 shares
·
$4,022
BURNETT JOSEPH MICHAEL
Chief Executive Officer
2026-03-19
20,942 shares
·
$67,852
BURNETT JOSEPH MICHAEL
Chief Executive Officer
2026-03-12
84,829 shares
D'ALESSANDRO DANILO
Chief Financial Officer
2026-03-12
32,627 shares
STIGALL L JEREMY
Officer
2026-03-12
30,995 shares
SABRA MAZIN
Chief Operating Officer
2026-03-12
26,101 shares
D'ALESSANDRO DANILO
Chief Financial Officer
2026-03-11
4,145 shares
STIGALL L JEREMY
Officer
2026-03-11
8,291 shares
BURNETT JOSEPH MICHAEL
Chief Executive Officer
2026-03-06
47,407 shares
D'ALESSANDRO DANILO
Chief Financial Officer
2026-03-06
18,765 shares
STIGALL L JEREMY
Officer
2026-03-06
17,778 shares
SABRA MAZIN
Chief Operating Officer
2026-03-06
13,827 shares
BURNETT JOSEPH MICHAEL
Chief Executive Officer
2026-03-03
26,568 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
2 analysts
B. Riley Securities
2026-03-18
Buy
Buy
B. Riley Securities
2026-03-05
Buy
Buy
Past News Coverage
Recent headlines mentioning CLPT from our newsroom.
Newest → oldest
No matching news yet.